XML 72 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Consolidation
9 Months Ended
Jun. 30, 2013
Basis of Presentation and Consolidation  
Basis of Presentation and Consolidation

Note A — Basis of Presentation and Consolidation

 

The accompanying unaudited condensed consolidated financial statements which have been derived from the Company’s audited financial statements as of September 30, 2012 and the unaudited June 30, 2013 and 2012 condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission which include the instructions to Form 10-Q.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  Certain reclassifications have been made to the prior year financial statements to conform to the current year presentation.  These reclassifications had no net effect on previously reported results of operations.  These financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Form 10-K for the year ended September 30, 2012.  In the opinion of management, the unaudited condensed consolidated financial statements contain all recurring adjustments considered necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods presented.  Operating results for the three and nine-month periods ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending September 30, 2013.

 

The accompanying financial statements include the accounts of Rochester Medical Corporation, Rochester Medical Limited, its wholly owned subsidiary in the United Kingdom, and Rochester Medical B.V., its wholly owned subsidiary in the Netherlands.  During fiscal 2013, the Company changed the name of its subsidiary Laprolan B.V. to Rochester Medical B.V.